{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "ADPT",
  "name": "Adaptive Biotechnologies Corporation",
  "url": "https://orbyd.app/dossiers/ADPT/",
  "json_url": "https://orbyd.app/dossiers/ADPT.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "clonoSEQ MRD pure-play inflecting to self-funding growth (MRD rev +53% YoY, profitability turning); June 15 Immune Medicine separation adds a value-unlock leg. But the tape just broke to fresh 52-wk highs (~$22.92) above the $20–22 sell-side band, running into a binary July 29 Q2 print — extension plus imminent earnings, not a clean fresh entry.",
  "invalidation_trigger": "A weekly close below $18 loses the rising 20-week base and the June–July breakout shelf above the old $20–22 sell-side band; a push-out of the positive end-2026 adjusted-EBITDA/FCF target on the July 29 print, or the theme flipping to SATURATED, would confirm the inflection break.",
  "catalyst_date": "2026-07-29",
  "outcome": "PLAYED_OUT",
  "outcome_date": "2026-06-24",
  "invalidation_fired": false,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Q2 2026 earnings scheduled Aug 5 2026 — binary; avoid fresh entries within 3 trading days of the print.",
    "Load-bearing fundamental claim is positive company-wide adjusted EBITDA + FCF by end-2026; a push-out breaks the inflection thesis.",
    "Pharma milestone revenue is lumpy ($9.0M in Q1 2026, first US primary-endpoint milestone) — strip it out when judging clean MRD growth trend.",
    "~95% revenue concentration in clonoSEQ MRD; Immune Medicine / Genentech TCR partnership is optionality, not a current driver.",
    "Cash $237.2M at Mar 31 2026 funds the path to self-sustaining — low near-term dilution risk.",
    "Q2 2026 earnings ~Aug 5 2026 — binary print; avoid fresh entries within 3 trading days.",
    "$300M convertible notes due 2031 priced June 17 2026 (upsized from $250M) — repays OrbiMed secured debt + funds buybacks; convert-arb delta hedging is a near-term equity headwind that can cap the rip.",
    "Business separation of MRD vs Immune Medicine announced June 15 2026; 'preferred path by year-end 2026' — structure/timeline/terms undecided, value-unlock optionality not a dated catalyst.",
    "Load-bearing fundamental claim: positive company-wide adjusted EBITDA + FCF by end-2026; a push-out breaks the inflection thesis.",
    "Pharma milestone revenue is lumpy ($9.0M Q1 2026, first US primary-endpoint milestone) — strip it out when judging the clean MRD growth trend.",
    "Cash $237.2M at Mar 31 2026 plus convert proceeds funds the path to self-sustaining — low near-term equity-raise dilution risk.",
    "Prior catalyst date 2026-06-14 (ASCO/EHA) has elapsed; next dated binary is Aug 5 earnings, outside the 30-day window.",
    "Q2 2026 earnings moved to July 29 2026 (after close, call 1:30pm PT) — binary; avoid fresh entries within 3 trading days (~July 24 onward).",
    "Price has run above the $20–22 analyst band to a new 52-wk high near $23.15 (July 15) — the 'under the band with room' edge that defined the June setup is now spent; only TD Cowen $25 (July 15) sits above spot, MS $20 (July 9) below.",
    "Load-bearing fundamental claim: positive company-wide adjusted EBITDA + FCF by end-2026; a push-out on the July 29 print breaks the inflection thesis.",
    "Pharma milestone revenue is lumpy ($9.0M in Q1 2026, first US primary-endpoint milestone) — strip it out when judging the clean MRD growth trend.",
    "~95% revenue concentration in clonoSEQ MRD; Immune Medicine separation ('preferred path by year-end 2026') is undated value-unlock optionality, not a current driver.",
    "$300M convertible notes due 2031 priced June 17 2026 (upsized from $250M) — convert-arb delta hedging is a mechanical near-term equity headwind that can cap the rip.",
    "No stock split has occurred — 160M shares / $3.67B cap confirms the ~$23 tape is unadjusted (a July 2026 '1-for-4 split' data point was spurious)."
  ],
  "body_markdown": "## Current Thesis\nThe clonoSEQ measurable-residual-disease (MRD) franchise is inflecting from chronic cash-burn into a self-funding growth story, and on June 15 2026 management added a value-unlock leg by announcing a planned separation of the Immune Medicine business — recasting Adaptive as a pure-play MRD diagnostics name while the life-sciences-tools-diagnostics narrative runs hot. What has changed since June: the tape has done its work. Shares closed $22.92 on July 17 2026 (+3.7% on the day) after tagging a fresh 52-week high near $23.15 on July 15, so the \"trading under the $20–22 sell-side band with room\" edge that defined the June setup is spent. Price now sits at the top of the analyst range with a binary Q2 print eleven days out (July 29). The narrative is accelerating; the entry no longer is.\n\n## Bull Case\n- Q1 2026 (reported May 5): total revenue $70.9M, +35% YoY; MRD segment $67.1M, +53% YoY, now ~95% of revenue — the growth is concentrated in the franchise the market is repricing.\n- clonoSEQ test volume 32,595 in Q1 2026, +41% YoY; the FY2026 framework calls for >30% volume growth, so the unit engine (not price/mix) is carrying the line.\n- Profitability inflection: Q1 adjusted EBITDA loss narrowed to -$2.5M from -$12.7M a year prior; FY2025 adjusted EBITDA was +$12.2M vs -$80.4M in 2024; target is positive company-wide adjusted EBITDA AND free cash flow by end-2026.\n- FY2026 MRD revenue guide raised to $260–270M (+22–27%) on the May 5 print; first U.S. primary-endpoint pharma milestone ($9.0M) recognized in Q1.\n- June 15–16: planned separation of MRD and Immune Medicine, targeting a \"preferred path by year-end 2026,\" sharpening the pure-play story.\n- June 17: priced an upsized $300M convertible (from $250M) due 2031 — repays OrbiMed secured debt, funds buybacks and growth, and extends runway past the end-2026 cash-flow inflection.\n- ASCO (May 29–Jun 3) + EHA (Jun 11–14): clonoSEQ featured in 33 presentations (1 plenary, 14 orals) across MM/CLL/ALL/lymphoma, embedding MRD as the default endpoint for the bispecific/CAR-T/quadruplet drug wave.\n- Sell-side keeps ratcheting: TD Cowen raised to $25 (Buy) on July 15; Guggenheim to $22 (Buy) on June 29. PT revisions are chasing the tape upward, not fading it.\n\n## Bear Case\n- Price has caught the band. Spot ~$22.92 now trades above Guggenheim $22, BTIG $22, JPMorgan $21 and Morgan Stanley $20 (Equal-Weight, raised July 9 but still below market). Only TD Cowen's $25 leaves upside; blended consensus (~$20.57) sits roughly at the market. The \"gap to targets\" that powered the June leg is closed.\n- A fresh entry at the 52-week high runs straight into the July 29 binary. Buying extension the week before an earnings print that has to validate the profitability inflection is paying up for the setup at its most fragile moment.\n- Convertible-arb delta hedging from the $300M issue means funds short the equity against the bond — mechanical selling pressure that can cap the rip even with improving fundamentals.\n- Separation is a target, not a transaction: only a \"preferred path by year-end 2026\" is committed, with no structure, timeline, or terms. Value-unlock theses on undecided spins routinely sit dead-money for quarters.\n- Still not GAAP-profitable. Positive adjusted EBITDA + FCF by year-end is a goal; any slippage on the July 29 print resets the inflection multiple the stock leans on.\n- ~95% revenue concentration in one product; the $9.0M Q1 pharma milestone is lumpy and flatters the headline growth rate — the clean MRD trend reads lower once it is stripped out.\n- Competitive/reimbursement risk: Natera and Guardant push tissue-free and ctDNA MRD; a payer or guideline tilt toward a rival assay pressures clonoSEQ volume directly.\n\n## Setup & Price Structure\n52-week range $9.96–$23.15; market cap ~$3.67B on ~160M shares; no split has occurred. The stock has roughly tripled off the single-digit low and printed a new high on July 15 2026, closing July 17 at $22.92, about 1% under that high. The multi-month base-and-breakout structure off single digits remains intact and the trend is up, but momentum has now pushed price through the entire cluster of analyst marks — a change of character from the June regime, where the tape sat beneath the band. The rising 20-week base is well below current levels; the June–July breakout shelf near the old $20–22 resistance is the first structural support to watch on any unwind. Sentiment reads late-cyclical for the move: new 52-week highs, PT chases, and mainstream \"still a buy?\" coverage all cluster here. For a momentum book the trend is the setup, but the specific reward-to-risk of a fresh entry at the high, into a print, with targets already met, is thin. Standing aside until the July 29 numbers clear the inflection question — or until price bases above the breakout shelf — is the cleaner path than chasing the last dollar to TD Cowen's $25.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-07-29** — Q2 2026 earnings, after market close, call 1:30 p.m. PT. Binary. The load-bearing checks: MRD volume growth holding >30%, MRD revenue tracking the $260–270M FY guide, and credible progress toward positive company-wide adjusted EBITDA + FCF by end-2026. Avoid fresh entries inside the ~3-trading-day window (from ~July 24) into the print.\n- **Ongoing (no fixed date)** — Immune Medicine separation \"preferred path by year-end 2026\"; watch for any 8-K disclosing structure/terms, which would convert optionality into a dated event.\n- **Ongoing** — convertible delta-hedging flow from the June $300M issue remains a mechanical headwind, not a scheduled event.\n- No FDA/PDUFA-dated events in the window.\n\n## Elapsed catalysts\n\n- **~2026-07-24 onward** — pre-earnings blackout / elevated binary risk window opens. *(passed 4d ago)*\n\n## What Would Change Our Mind\nStructurally, a weekly close below $18 loses the rising 20-week base and the June–July breakout shelf above the old $20–22 sell-side band, flipping the momentum read from continuation to failed breakout. Fundamentally, a push-out of the positive end-2026 adjusted-EBITDA/FCF target on the July 29 print breaks the inflection thesis the multiple rests on; treat the pharma-milestone line as noise and read the clean MRD trend before reacting. A theme transition of life-sciences-tools-diagnostics to SATURATED — mainstream coverage saturating with no new sub-narrative — would remove the tailwind that justifies paying up here. On the other side, a clean beat-and-raise on July 29 that confirms the profitability turn, plus a defined separation structure, would re-open a higher-conviction entry on the first constructive pullback to the breakout shelf.\n\n## Correlation Notes\nADPT trades with the MRD/liquid-biopsy diagnostics complex — Natera (NTRA), Guardant (GH), Exact Sciences (EXAS) — and more broadly with life-sciences-tools names; cluster strength across those peers is confirmation, cluster rollover is the early tell that the theme is tiring. As an unprofitable-until-2026 small/mid-cap biotech, it carries high beta to long-duration risk appetite: a macro tightening impulse or biotech (XBI/IBB) drawdown pressures the multiple independent of clonoSEQ execution. Idiosyncratic drivers dominate over the next two weeks — the July 29 print and any separation disclosure will move the stock more than the tape — but the convertible-hedging overhang links near-term price action to volatility conditions rather than fundamentals alone.",
  "first_seen": "2026-06-11",
  "last_analyzed": "2026-07-20T07:28:59+00:00",
  "last_update_source": "theme_discovery",
  "license": "Content © orbyd. Cite the canonical URL."
}